Hepatoid Adenocarcinoma of the Lung With EGFR Mutation and the Response to Tyrosine Kinase Inhibitor

被引：0
|
作者：
Chen, H. [1 ]
Wang, W. [2 ]
Li, X. [1 ]
Xu, C. [3 ]
Zhu, Y. [1 ]
Du, K. [1 ]
Fang, M. [2 ]
机构：
[1] Zhejiang Rongjun Hosp, Jiaxing, Peoples R China
[2] Zhejiang Canc Hosp, Hangzhou, Peoples R China
[3] Fujian Canc Hosp, Fuzhou, Peoples R China
来源：
JOURNAL OF THORACIC ONCOLOGY | 2021年 / 16卷 / 03期
关键词：
Hepatoid adenocarcinoma; EGFR mutation; tyrosine kinase inhibitor;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P76.02
引用
收藏
页码：S585 / S585
页数：1
相关论文
共 50 条
  • [1] The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients
    Sarosi, Veronika
    Baliko, Zoltan
    Smuk, Gabor
    Laszlo, Terezia
    Szabo, Mariann
    Ruzsics, Istvan
    Mezosi, Emese
    PATHOLOGY & ONCOLOGY RESEARCH, 2016, 22 (04) : 755 - 761
  • [2] Management of tyrosine kinase inhibitor resistance in lung cancer with EGFR mutation
    Becker, Kevin
    Xu, Yiqing
    WORLD JOURNAL OF CLINICAL ONCOLOGY, 2014, 5 (04): : 560 - 567
  • [3] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
    Eun Young Kim
    Arum Kim
    Gaeun Lee
    Hangsuck Lee
    Yoon Soo Chang
    BMC Cancer, 18
  • [4] Different mutational characteristics of the subsets of EGFR-tyrosine kinase inhibitor sensitizing mutation-positive lung adenocarcinoma
    Kim, Eun Young
    Kim, Arum
    Lee, Gaeun
    Lee, Hangsuck
    Chang, Yoon Soo
    BMC CANCER, 2018, 18
  • [5] Association of EGFR Tyrosine Kinase Inhibitor Treatment With Progression-Free Survival Among Taiwanese Patients With Advanced Lung Adenocarcinoma and EGFR Mutation
    Chen, Po-Yen
    Wang, Chin-Chou
    Hsu, Chien-Ning
    Chen, Chung-Yu
    FRONTIERS IN PHARMACOLOGY, 2021, 12
  • [6] EGFR Mutation Status in Lung Adenocarcinoma-Associated Malignant Pleural Effusion and Efficacy of EGFR Tyrosine Kinase Inhibitors
    Yang, Jiyoul
    Lee, Ok-Jun
    Son, Seung-Myoung
    Woo, Chang Gok
    Jeong, Yusook
    Yang, Yaewon
    Kwon, Jihyun
    Lee, Ki Hyeong
    Han, Hye Sook
    CANCER RESEARCH AND TREATMENT, 2018, 50 (03): : 908 - 916
  • [7] SEVERAL RECEPTOR TYROSINE KINASE IS ACTIVATED BUT ORCHESTRATED BY EGFR IN EGFR-TKI ACQUIRED RESISTANT LUNG ADENOCARCINOMA CELLS WITH EGFR MUTATION
    Suda, Kenichi
    Mizuuchi, Hiroshi
    Sato, Katsuaki
    Takemoto, Toshiki
    Iwasaki, Takuya
    Minami, Kenji
    Yatabe, Yasushi
    Mitsudomi, Tetsuya
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S771 - S772
  • [8] EGFR Tyrosine Kinase Inhibitor and Chemotherapy in EGFR Mutation-Positive Non-Small Cell Lung Cancer
    Nishino, Kazumi
    Kimura, Madoka
    Inoue, Takako
    Uchida, Junji
    Kumagai, Toru
    Imamura, Fumio
    JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (09) : S526 - S526
  • [9] Pulmonary Adenoid Cystic Carcinoma with EGFR Activating Mutation and Responds Well with Tyrosine Kinase Inhibitor
    Zaini, J.
    Andarini, S.
    Syahruddin, E.
    Hudoyo, A.
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2145 - S2145
  • [10] SIMILAR EFFICACY OF EGFR TYROSINE KINASE INHIBITORS REGARDLESS OF TREATMENT SEQUENCE FOR THE PATIENTS WITH EGFR MUTATION-POSITIVE PULMONARY ADENOCARCINOMA
    Koo, Dong Hoe
    Kim, Kyu-Pyo
    Choi, Chang-Min
    Lee, Dae-Ho
    Lee, Jae Cheol
    Lee, Jung-Shin
    Jang, Se Jin
    Kim, Sang-We
    JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S409 - S410
12345